NCT02187705

Brief Summary

The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,688

participants targeted

Target at P75+ for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 1999

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2000

Completed
14.2 years until next milestone

First Submitted

Initial submission to the registry

July 9, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 11, 2014

Completed
Last Updated

July 11, 2014

Status Verified

July 1, 2014

Enrollment Period

1 year

First QC Date

July 9, 2014

Last Update Submit

July 10, 2014

Conditions

Hypertension

Outcome Measures

Primary Outcomes (2)

  • Changes from baseline in blood pressure

    Evaluation was performed separately for three patient groups depending on their hypertension status at baseline (normotension, essential hypertension and isolated hypertension)

    Up to 14 days

  • Number of patients with adverse events

    Up to 14 days

Study Arms (3)

Patients with normotension at baseline

Drug: Telmisartan tablets

Patients with essential hypertension at baseline

Drug: Telmisartan tablets

Patients with isolated hypertension at baseline

Drug: Telmisartan tablets

Interventions

Telmisartan tabletsDRUG

All patients were treated with different doses of telmisartan for 14 days

Also known as: Micardis®
Patients with essential hypertension at baselinePatients with isolated hypertension at baselinePatients with normotension at baseline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with essential hypertension
  • Minimum age of 18 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hypertension

Interventions

Telmisartan

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Biphenyl CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2014

First Posted

July 11, 2014

Study Start

May 1, 1999

Primary Completion

May 1, 2000

Last Updated

July 11, 2014

Record last verified: 2014-07